Cascadian Therapeutics Enlarging Breast Cancer Drug Study

Cascadian Therapeutics is expanding its clinical trial for its breast cancer drug tucatinib. If successful, the enlarged study will be sufficient to file for approval.  The company is enrolling new patients and hopes to have results by 2020. Additional cash must be raised to complete the enlarged study. Cascadian Therapeutics is in the midst of a turnaround following years of ineffective research and development, and its stock price is down 69% over the past year. Tucatinib is designed to block HER2, a tumor-growing protein overexposed in breast cancer.